7147 results for "canc*"

in 9.22 milliseconds.

• Normal sample for patient SA598

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA598

  Dataset EGAD00001009246

• Normal sample for patient SA600

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA600

  Dataset EGAD00001009248

• Normal sample for patient SA667

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA667

  Dataset EGAD00001009253

• Tumour sample for patient SA604

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA604

  Dataset EGAD00001009260

• Normal sample for patient SA601

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA601

  Dataset EGAD00001009249

• Normal sample for patient SA654

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA654

  Dataset EGAD00001009250

• Widespread hypertranscription in aggressive human cancers

  Data used to validate RNAmp tool.

  Dataset EGAD00001009285

• Colorectal cancer samples WES

  The whole exome was sequenced in two cancer-affected members (II:1 and III:1) of the family. The family subject of this study showed an autosomal dominant mode of CRC inheritance, fulfilling the Amsterdam I clinical criteria with three CRCs in two consecutive generations. The exome capture was performed using SureSelectXT Human All Exon V3 (51Mb, Agilent Technologies), and the library was sequenced on an Illumina HiSeq 2000 platform with paired-end reads of 101bp and a 50x average coverage depth.

  Dataset EGAD00001009170

• POETIC clinical Trial Ki67 Bookend Breast Cancer Targeted Exome and RNAseq Project

  Using RNAseq, we compare the 15% of poorest responders (PRs, n=177) as measured by proportional Ki67 changes after 2 weeks of neoadjuvant aromatase inhibitors to good responders (GRs, n=190) selected from the top 50% responders in the POETIC trial and matched for baseline Ki67 categories. In the POETIC trial, 4,480 postmenopausal women with primary ER+ BC were randomised 2:1 to receive either treatment with a non-steroidal AI (letrozole or anastrozole) for 2 weeks before and 2 weeks after surgery or to no perisurgical treatment. Only AI-treated patients with HER2- tumors, paired baseline and surgery Ki67 available, and baseline Ki67 immunohistochemistry (IHC) >10% (to minimise imprecision in proportional Ki67 falls) were included for selection. Data is baseline RNAseq and targeted exome DNA sequencing analysis of POETIC Good/Poor Responders to aromatase inhibitors based on change in Ki67.

  Dataset EGAD00001010919

• Normal sample for patient SA668

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA668

  Dataset EGAD00001009254